| Evolved Cas9 variants with broad PAM compatibility and high DNA specificity JH Hu, SM Miller, MH Geurts, W Tang, L Chen, N Sun, CM Zeina, X Gao, ... Nature 556 (7699), 57-63, 2018 | 1689 | 2018 |
| Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo JA Zuris, DB Thompson, Y Shu, JP Guilinger, JL Bessen, JH Hu, ... Nature biotechnology 33 (1), 73-80, 2015 | 1620 | 2015 |
| Treatment of autosomal dominant hearing loss by in vivo delivery of genome editing agents X Gao, Y Tao, V Lamas, M Huang, WH Yeh, B Pan, YJ Hu, JH Hu, ... Nature 553 (7687), 217-221, 2018 | 569 | 2018 |
| Aptazyme-embedded guide RNAs enable ligand-responsive genome editing and transcriptional activation W Tang, JH Hu, DR Liu Nature communications 8 (1), 15939, 2017 | 238 | 2017 |
| A programmable Cas9-serine recombinase fusion protein that operates on DNA sequences in mammalian cells B Chaikind, JL Bessen, DB Thompson, JH Hu, DR Liu Nucleic acids research 44 (20), 9758-9770, 2016 | 154 | 2016 |
| Structure and mechanism of the UvrA–UvrB DNA damage sensor D Pakotiprapha, M Samuels, K Shen, JH Hu, D Jeruzalmi Nature structural & molecular biology 19 (3), 291-298, 2012 | 90 | 2012 |
| CRISPR/Cas9‐mediated fluorescent tagging of endogenous proteins in human pluripotent stem cells A Sharma, CN Toepfer, T Ward, L Wasson, R Agarwal, DA Conner, JH Hu, ... Current protocols in human genetics 96 (1), 21.11. 1-21.11. 20, 2018 | 86 | 2018 |
| Switchable gRNAs comprising aptamers DR Liu, JH Hu US Patent 9,228,207, 2016 | 83 | 2016 |
| MRNA-sensing switchable gRNAs DR Liu, JH Hu US Patent 9,340,799, 2016 | 82 | 2016 |
| Switchable Cas9 nucleases and uses thereof DR Liu, JH Hu US Patent 10,597,679, 2020 | 74 | 2020 |
| Extended DNA-sensing GRNAS DR Liu, JH Hu US Patent 9,340,800, 2016 | 72 | 2016 |
| Chemical biology approaches to genome editing: understanding, controlling, and delivering programmable nucleases JH Hu, KM Davis, DR Liu Cell chemical biology 23 (1), 57-73, 2016 | 68 | 2016 |
| Switchable CAS9 nucleases and uses thereof DR Liu, JH Hu US Patent 11,299,755, 2022 | 44 | 2022 |
| Efficient delivery of genome-editing proteins in vitro and in vivo JA Zuris, DB Thompson, Y Shu, JP Guilinger, JL Bessen, JH Hu, ... Nature biotechnology 33 (1), 73, 2014 | 42 | 2014 |
| Evolved Cas9 proteins for gene editing DR Liu, JH Hu US Patent 12,043,852, 2024 | 40 | 2024 |
| Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation W Tang, JH Hu, DR Liu US Patent 11,560,566, 2023 | 33 | 2023 |
| Treatment of monogenic and digenic dominant genetic hearing loss by CRISPR-Cas9 ribonucleoprotein delivery in vivo Y Tao, V Lamas, W Du, W Zhu, Y Li, MN Whittaker, JA Zuris, ... Nature communications 14 (1), 4928, 2023 | 25 | 2023 |
| Evolved cas9 variants and uses thereof DR Liu, JH Hu US Patent App. 16/976,047, 2022 | 13 | 2022 |
| Switchable cas9 nucleases and uses thereof DR Liu, JH Hu US Patent App. 17/688,416, 2023 | 12 | 2023 |
| Baire one functions J Hu, A Lum, J Menashe, S Miller, D Ozog preprint, 0 | 2 | |